# Evaluating Isradipine for Cognitive Enhancement in Schizophrenia and Schizoaffective Disorder

> **NCT01658150** · NA · COMPLETED · sponsor: **Icahn School of Medicine at Mount Sinai** · enrollment: 11 (actual)

## Conditions studied

- Schizophrenia
- Schizoaffective Disorder

## Interventions

- **DRUG:** isradipine

## Key facts

- **NCT ID:** NCT01658150
- **Lead sponsor:** Icahn School of Medicine at Mount Sinai
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-09
- **Primary completion:** 2018-01-02
- **Final completion:** 2018-01-02
- **Target enrollment:** 11 (ACTUAL)
- **Last updated:** 2018-12-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01658150

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01658150, "Evaluating Isradipine for Cognitive Enhancement in Schizophrenia and Schizoaffective Disorder". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01658150. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*